MiNK Therapeutics Stock Forecast, Price & News

MiNK Therapeutics (NASDAQ:INKT) Frequently Asked Questions

Is MiNK Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MiNK Therapeutics stock.
View analyst ratings for MiNK Therapeutics or view top-rated stocks.

What price target have analysts set for INKT?

4 brokerages have issued 1 year target prices for MiNK Therapeutics' shares. Their forecasts range from $24.00 to $30.00. On average, they expect MiNK Therapeutics' stock price to reach $26.67 in the next year. This suggests a possible upside of 100.8% from the stock's current price.
View analysts' price targets for MiNK Therapeutics or view top-rated stocks among Wall Street analysts.

Who are some of MiNK Therapeutics' key competitors?

Some companies that are related to MiNK Therapeutics include Ginkgo Bioworks (DNA), ImmunityBio (IBRX), Allogene Therapeutics (ALLO), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), Revolution Medicines (RVMD), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), C4 Therapeutics (CCCC), Vericel (VCEL), Alector (ALEC), Immunocore (IMCR), Atara Biotherapeutics (ATRA), Inhibrx (INBX) and Coherus BioSciences (CHRS).
View all of INKT's competitors.

When did MiNK Therapeutics IPO?

(INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share.

What is MiNK Therapeutics' stock symbol?

MiNK Therapeutics trades on the NASDAQ under the ticker symbol "INKT."

When did the company's quiet period expire?

MiNK Therapeutics' quiet period expired on Wednesday, November 24th. MiNK Therapeutics had issued 3,333,334 shares in its initial public offering on October 15th. The total size of the offering was $40,000,008 based on an initial share price of $12.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of MiNK Therapeutics?

Shares of INKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiNK Therapeutics' stock price today?

One share of INKT stock can currently be purchased for approximately $13.28.

How much money does MiNK Therapeutics make?

MiNK Therapeutics has a market capitalization of $432.80 million.

What is MiNK Therapeutics' official website?

The official website for MiNK Therapeutics is www.minktherapeutics.com.

How can I contact MiNK Therapeutics?

The company can be reached via phone at 212-994-8250 or via email at [email protected].